866-997-4948(US-Canada Toll Free)

BioLingus AG - Product Pipeline Review - 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 30 Pages

BioLingus AG - Product Pipeline Review - 2016

Summary

Global Markets Directs, BioLingus AG - Product Pipeline Review - 2016, provides an overview of the BioLingus AGs pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by BioLingus AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of BioLingus AG
- The report provides overview of BioLingus AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses BioLingus AGs pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features BioLingus AGs out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate BioLingus AGs strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for BioLingus AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding BioLingus AGs pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
BioLingus AG Snapshot 6
BioLingus AG Overview 6
Key Facts 6
BioLingus AG - Research and Development Overview 7
Key Therapeutic Areas 7
BioLingus AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
BioLingus AG - Pipeline Products Glance 11
BioLingus AG - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
BioLingus AG - Unknown Stage Pipeline Products 13
Unknown Products/Combination Treatment Modalities 13
BioLingus AG - Drug Profiles 14
aldesleukin - Drug Profile 14
Product Description 14
Mechanism Of Action 14
R&D Progress 14
Cellular Immunotherapy to Target Survivin for Oncology - Drug Profile 15
Product Description 15
Mechanism Of Action 15
R&D Progress 15
exenatide biobetter - Drug Profile 16
Product Description 16
Mechanism Of Action 16
R&D Progress 16
interferon alfa biobetter - Drug Profile 17
Product Description 17
Mechanism Of Action 17
R&D Progress 17
interferon gamma - Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
interleukin 2 - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
Monoclonal Antibody to Inhibit IL-23 for Crohn's Disease and Psoriasis - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
Synthetic Peptide to Agonize GLP-1 for Type 2 Diabetes - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
Synthetic Peptide to Inhibit TNF-Alpha for Rheumatoid Arthritis - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
BioLingus AG - Pipeline Analysis 24
BioLingus AG - Pipeline Products by Target 24
BioLingus AG - Pipeline Products by Route of Administration 25
BioLingus AG - Pipeline Products by Molecule Type 26
BioLingus AG - Pipeline Products by Mechanism of Action 27
BioLingus AG - Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 29
Disclaimer 30

List of Tables
BioLingus AG, Key Facts 6
BioLingus AG - Pipeline by Indication, 2016 8
BioLingus AG - Pipeline by Stage of Development, 2016 9
BioLingus AG - Monotherapy Products in Pipeline, 2016 10
BioLingus AG - Preclinical, 2016 11
BioLingus AG - Discovery, 2016 12
BioLingus AG - Unknown, 2016 13
BioLingus AG - Pipeline by Target, 2016 24
BioLingus AG - Pipeline by Route of Administration, 2016 25
BioLingus AG - Pipeline by Molecule Type, 2016 26
BioLingus AG - Pipeline Products by Mechanism of Action, 2016 27

List of Figures
BioLingus AG - Pipeline by Top 10 Indication, 2016 8
BioLingus AG - Pipeline by Stage of Development, 2016 9
BioLingus AG - Monotherapy Products in Pipeline, 2016 10
BioLingus AG - Pipeline Target, 2016 24
BioLingus AG - Pipeline by Route of Administration, 2016 25
BioLingus AG - Pipeline by Molecule Type, 2016 26
BioLingus AG - Pipeline Products by Mechanism of Action, 2016 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *